성인 급성 백혈병 환자의 항암화학요법 유발 오심 구토(chemotherapy-induced nausea and vomiting) 예방에 있어서 granisetron transdermal system patch제의 효과 분석
The Effect of Granisetron Transdermal System Patch for the Prevention of Chemotherapy-induced Nausea and Vomiting in Adult Patients with Acute Leukemia
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background : Granisetron transdermal system patch offers convenient non-invasiveoption and could enable continuous antiemetic effects during multi-day chemotherapy for acuteleukemia patients. This study compare the effect and costs of granisetron transdermal systempatch with ramosetron treatment for control chemotherapy-induced nausea and vomiting. Methods : From January 2011 to September 2013, one-hundred fifty acute leukemia patientswere prescribed with antiemetic prophylaxis granisetron transdermal system patch andramosetron. These patients were classified into granisetron group(n=82) and ramosetrongroup(n=68) and the effect and costs of each group were evaluated. Results : Total response was achieved by 51.2% of granisetron group and 45.6% of ramosetrongroup, but the difference not statistically significant(p=0.492). The first emetic episode occurred median Day1(1-9) granisetron group and median Day3(1-7) ramosetron group including patientswith failure to emetic control. Conclusions : ranisetron transdermal system patch offers reliable antiemetic effect and preferabledosing for patients receiving multi-day chemotherapy with acute leukemia, and close dosingcontrol pharmacist is to achieve higher response.
Abstract
Background : Granisetron transdermal system patch offers convenient non-invasiveoption and could enable continuous antiemetic effects during multi-day chemotherapy for acuteleukemia patients. This study compare the effect and costs of granisetron transdermal systempatch with ramosetron treatment for control chemotherapy-induced nausea and vomiting. Methods : From January 2011 to September 2013, one-hundred fifty acute leukemia patientswere prescribed with antiemetic prophylaxis granisetron transdermal system patch andramosetron. These patients were classified into granisetron group(n=82) and ramosetrongroup(n=68) and the effect and costs of each group were evaluated. Results : Total response was achieved by 51.2% of granisetron group and 45.6% of ramosetrongroup, but the difference not statistically significant(p=0.492). The first emetic episode occurred median Day1(1-9) granisetron group and median Day3(1-7) ramosetron group including patientswith failure to emetic control. Conclusions : ranisetron transdermal system patch offers reliable antiemetic effect and preferabledosing for patients receiving multi-day chemotherapy with acute leukemia, and close dosingcontrol pharmacist is to achieve higher response.
참고문헌 (10)
- Tuca A, "Use of granisetron transdermal system in the prevention of chemotherapyinduced nausea and vomiting: a review", Cancer Management and Research, 2, pp.1~12 (2010)
- Boccia R.V, "Efficacy and tolerability of transdermal granisetron for the control of chemotherapy-induced nausea and vomiting associated with moderately and highly emetogenic multi-day chemotherapy : a randomized, double-blind, phase Ⅲ study", Support Care Cancer, 19, pp.1609~1617 (2011)
- Boccia R.V, "Use of transdermal and intravenous granisetron and the ability of the Hesketh score to assess nausea and vomiting induced by multiday chemotherapy", Cancer Management and Research, 4, pp.171~176 (2012)
- Mattiuzzi G.N, "Daily palonosetron is superior to ondansetron in the prevention of delayed chemotherapyinduced nausea and vomiting in patients with acute myelogenous leukemia", Cancer, 116(24), pp.5659~5666 (2010)
- clinical practice guideline in oncology v.1, "NCCN", ~ (2014)
- Schwartzberg L., "Chemotherapy-induced nausea and vomiting: state of art in 2006", J Support Oncol, 4(suppl 1), pp.003~008 (2006)
- Lopez-Jimenez J., "Chemotherpayinduced nausea and vomiting in acute leukemia and stem cell transplant patients:results of a multicenter, observational study", Haematologica, 91(1), pp.84~91 (2006)
- Cheirsilpa A., "Comparison of ramosetron and granisetron for the prevention of acute and delayed emesis in cisplatin-based chemotherapy: a randomized controlled trial", Jpn J Clin Oncol, 35(12), pp.695~699 (2005)
- Rabasseda X., "Ramosetron, a 5-TH3 receptor antagonist for the control of nausea and vomiting", Drug Today(Barc)., 38(2), pp.75~89 (2002)
- Howell J., "Pharmacokinetics of a granisetron transdermal system for the treatment of chemotherapy-induced nausea and vomiting", J Oncol Pharm Pract, 15(4), pp.223~231 (2009)